H.R. 1266 Congress 119 session
Combating Illicit Xylazine Act
Status
- Introduced
- Committee
- Floor vote
- Passed
- Enacted
In committee — last recorded action July 21, 2026
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.
Passage likelihood
27% Lower than most bills at this stage
This is an estimate, not a guarantee. It is computed from the signals listed below and nothing else. It does not account for leadership priorities, floor scheduling, or negotiations that are not in the public record.
What the estimate is based on
- Historical base rate About 4% of introduced federal bills are enacted.
- Current stage Referred to committee.
- Cosponsors 113 cosponsors.
- Bipartisan cosponsorship Cosponsors come from 2 parties.
State-level impact
State-level impact data is not available for this bill. The source text does not contain a per-state funding formula or scored breakdown, so no figures are shown.
Official actions
- Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.
- Committee Consideration and Mark-up Session Held
- Committee Consideration and Mark-up Session Held
- Forwarded by Subcommittee to Full Committee by Voice Vote.
- Subcommittee Consideration and Mark-up Session Held
- Referred to the Subcommittee on Health.
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House
- Introduced in House